Wasatch Advisors’s Briacell Therapeutics BCTX Stock Holding History

Wasatch Advisors’s Portfolio BCTX Stock Details BCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,783	Closed	-$1.56M	–	251
2023 Q4	$1.56M	Sell	1,783 -1,642	-48%	-$1.18M	0.01%	232
2023 Q3	$3.21M	Sell	3,425 -656	-16%	-$642K	0.02%	221
2023 Q2	$3.93M	Sell	4,081 -26	-0.6%	-$25.7K	0.02%	219
2023 Q1	$4.59M	Buy	4,107 +1,396	+51%	+$1.45M	0.03%	211
2022 Q4	$1.78M	Buy	2,711 +353	+15%	+$299K	0.01%	239
2022 Q3	$1.99M	Sell	2,358 -19	-0.8%	-$19.1K	0.01%	228
2022 Q2	$2.06M	Buy	2,377 +746	+46%	+$737K	0.01%	232
2022 Q1	$2.48M	Buy	+1,631	New	+$1.93M	0.01%	242

Other funds holding BCTX

LCM

Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

RAM

Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return

KJHP

K.J. Harrison & Partners Toronto, Ontario, Canada $608M AUM 45.31% 1-Year Est. Return

OBWG

Onyx Bridge Wealth Group Tarrytown, New York $1.11B AUM 24.65% 1-Year Est. Return

STA

Summit Trail Advisors New York $6.98B AUM 19.51% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Wasatch Advisors's BCTX Position: Q1 2024 in Review

Wasatch Advisors sold out of Briacell Therapeutics (BCTX) in Q1 2024, closing a stake of 1,783 shares — an estimated $1.56M sold.

Wasatch Advisors first reported a position in BCTX in Q1 2022 and held it in 8 quarters. The position peaked at $4.59M in Q1 2023. 19 funds tracked by Wall St. Rank hold BCTX as of Q1 2024.

Wasatch Advisors reported no remaining Briacell Therapeutics position as of Q1 2024 after selling out during the quarter.
Wasatch Advisors sold 1,783 Briacell Therapeutics shares in Q1 2024, an estimated $1.56M.
Wasatch Advisors first reported a position in Briacell Therapeutics in Q1 2022 and held it in 8 quarters.
Wasatch Advisors's Briacell Therapeutics position peaked at $4.59M in Q1 2023.
19 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q1 2024.

Based on Wasatch Advisors's 13F filing for Q1 2024, filed 18 Apr 2024.